Skip to content
New: free dose calculator with 14 peptide presets. No signup.
Peptides Academy

KPV + BPC-157 + Thymosin Alpha-1 + LDN Autoimmune Stack

A four-component protocol addressing autoimmune dysregulation through complementary immunomodulatory mechanisms. KPV (alpha-MSH fragment) suppresses NF-κB and reduces pro-inflammatory cytokine production. BPC-157 promotes tissue repair and modulates nitric oxide signaling. Thymosin alpha-1 enhances regulatory T-cell function and restores immune balance. Low-dose naltrexone (LDN) upregulates endogenous endorphin and enkephalin production, which modulates immune cell activity through opioid growth factor receptors. The stack aims to rebalance — not suppress — the immune system.

Quick Comparison

PropertypeptideThe Autoimmune Stack: KPV + BPC-157 + Thymosin Alpha-1 + Low-Dose Naltrexone
SourceSalmon DNA fragmentsVarious sources
Primary MechanismA2A receptor activation, DNA repairVaries by ingredient
Key BenefitsTissue regeneration, anti-inflammation, collagen boostMultiple skin benefits
Best Time to ApplyAM or PMAM or PM
Can Combine?Generally compatible — check specific guidelines.

How to Use Together

This protocol is typically introduced gradually over 4–6 weeks. Week 1–2: begin LDN at 0.5–1 mg orally at bedtime, titrating up to 4.5 mg over several weeks (standard LDN titration). Week 2–3: add BPC-157 (250–500 mcg subcutaneously or orally, daily). Week 3–4: introduce KPV (200–600 mcg subcutaneously or orally, daily). Week 4–6: add thymosin alpha-1 (1.6 mg subcutaneously, 2–3 times weekly). This phased approach allows identification of any adverse reactions to individual components. Full protocol is maintained for 3–6 months with regular lab monitoring. LDN is often continued long-term; peptides are typically cycled.

Safety Notes

Autoimmune conditions are medically complex — this stack should complement, not replace, conventional immunological care. LDN is a prescription medication and should be obtained through a physician; it is contraindicated with concurrent opioid use (including opioid pain medications) as it blocks opioid receptors. Thymosin alpha-1 enhances immune function, which could theoretically worsen autoimmune flares in some individuals — close monitoring is essential during initiation. BPC-157 and KPV are research-grade with limited human autoimmune data. Never discontinue prescribed immunosuppressive or disease-modifying medications without physician guidance. Regular monitoring of inflammatory markers, disease-specific antibodies, and clinical symptoms is mandatory.

Recommended Products (4)

Frequently Asked Questions

How can thymosin alpha-1 help autoimmune conditions if it enhances immunity?
This is the critical distinction between immunostimulation and immunomodulation. Thymosin alpha-1 does not simply amplify all immune responses — it promotes the maturation and function of regulatory T-cells (Tregs), which are the immune system's brake mechanism against autoimmunity. It also enhances dendritic cell maturation, improving antigen presentation fidelity and potentially reducing the aberrant antigen recognition that drives autoimmune activity. The net effect in autoimmune contexts appears to be immune rebalancing rather than blanket stimulation. However, this nuance means careful monitoring is essential — individual responses vary.
What is the mechanism behind low-dose naltrexone for autoimmune disease?
At full doses (50 mg), naltrexone blocks opioid receptors continuously for addiction treatment. At low doses (1.5–4.5 mg at bedtime), it creates a brief 4–6 hour receptor blockade during sleep, triggering a compensatory upregulation of endogenous endorphins and met-enkephalin (opioid growth factor, OGF). These endogenous opioids modulate immune cell proliferation and function through OGF receptors on lymphocytes, reducing inflammatory cytokines (TNF-α, IL-6) and shifting the immune balance away from autoimmune hyperactivity. Over 100 published studies and several clinical trials support LDN in conditions including multiple sclerosis, Crohn's disease, and fibromyalgia.
Which autoimmune conditions has this stack been used for?
Components of this stack have been investigated in various autoimmune conditions. LDN has published clinical data in Crohn's disease, multiple sclerosis, and fibromyalgia. BPC-157 has preclinical data in inflammatory bowel disease models. KPV has demonstrated anti-inflammatory effects in colitis models. Thymosin alpha-1 has been studied as an immune modulator in hepatitis and as an adjunct in various immune-mediated conditions. The combined stack is most commonly discussed in integrative medicine contexts for Hashimoto's thyroiditis, rheumatoid arthritis, inflammatory bowel disease, psoriasis, and lupus — though controlled clinical data for the full combination does not exist.
Can I use this stack while on immunosuppressive medications?
With caution and physician oversight. LDN is generally compatible with most immunosuppressive medications except opioid-based pain medications. BPC-157 and KPV have no known interactions with immunosuppressants. The concern is thymosin alpha-1: enhancing immune function while simultaneously suppressing it with medications creates opposing signals. Some practitioners introduce thymosin alpha-1 as immunosuppressive doses are being reduced (under physician guidance), using it to support immune rebalancing during the tapering process. Never modify immunosuppressive medication doses based on peptide use without medical supervision.
Why is the phased introduction important?
Autoimmune conditions can flare unpredictably, and introducing four immunomodulatory agents simultaneously makes it impossible to identify which caused any adverse reaction. The phased approach serves two purposes: first, it allows attribution — if a flare occurs after adding thymosin alpha-1, you know what to adjust. Second, it allows the immune system to adapt gradually rather than receiving four simultaneous modulatory signals. LDN is introduced first because it has the most clinical precedent, the best-characterized titration schedule, and the mildest acute effects.
How do I know if my autoimmune condition is responding to this stack?
Objective markers: reduction in disease-specific antibodies (anti-TPO for Hashimoto's, RF/anti-CCP for RA, ANA for lupus), decreased inflammatory markers (CRP, ESR, calprotectin for IBD), improved organ-specific function tests (TSH normalization, joint imaging improvement). Subjective markers: reduced fatigue (often the first improvement reported), decreased joint pain or stiffness, improved digestive function, reduced skin manifestations, fewer flare episodes. Meaningful assessment requires 3–6 months of consistent use — autoimmune conditions respond slowly to immunomodulatory interventions.
Is LDN really effective or is it a placebo effect?
LDN has moved beyond anecdotal evidence. Published randomized controlled trials include: a 2013 RCT in Crohn's disease showing significant endoscopic improvement (Smith et al., American Journal of Gastroenterology), a 2010 crossover RCT in multiple sclerosis showing improved quality of life (Cree et al., Annals of Neurology), and multiple trials in fibromyalgia showing reduced pain and improved function. Mechanistically, the OGF-OGFr axis is well characterized, and endorphin upregulation with LDN has been confirmed in clinical studies. The evidence is not as robust as for established disease-modifying drugs, but it exceeds placebo-level support.
What are the most common side effects of this stack?
LDN: vivid dreams and mild sleep disturbance during the first 1–2 weeks (usually resolves; dosing earlier in the evening can help). BPC-157: injection site reactions (redness, mild pain). KPV: generally well tolerated; mild gastrointestinal effects with oral dosing. Thymosin alpha-1: injection site reactions, mild flu-like symptoms in the first few doses as immune activity shifts. The most concerning potential adverse effect is an autoimmune flare — particularly with thymosin alpha-1 initiation. Any worsening of autoimmune symptoms should prompt dose reduction or discontinuation of the most recently added component.
Can this stack put my autoimmune condition into remission?
Remission in autoimmune disease is multifactorial and depends on disease type, severity, duration, genetic factors, and environmental triggers. This stack may support immune rebalancing and symptom reduction, but claiming it induces remission would be unsupported by current evidence. LDN has documented cases of endoscopic remission in Crohn's disease. However, autoimmune remission typically requires addressing the full picture: gut barrier integrity, microbiome composition, environmental trigger removal (food antigens, toxins, infections), stress management, and sometimes pharmaceutical disease-modifying therapy. This stack is one piece of a comprehensive approach.

Other peptide Ingredient Combinations

The Anti-Aging Stack: GHK-Cu + Epitalon

GHK-Cu and Epitalon target two distinct hallmarks of aging — extracellular matrix degradation and te

The Athletic Performance Stack: IGF-1 LR3 + Ipamorelin + BPC-157

The athletic performance stack layers three peptides with distinct but complementary mechanisms to s

The Bone Health Stack: BPC-157 + Abaloparatide + Collagen Peptides

A three-component protocol addressing bone mineral density and bone quality. Abaloparatide is a synt

The Cardiac Protection Stack: TB-500 + SS-31 + Humanin

A three-peptide cardiovascular support stack targeting myocardial repair (TB-500), mitochondrial car

The Cognitive Stack: Semax + Selank

The classic Russian nootropic peptide pairing. Semax (an ACTH 4-10 analog) enhances BDNF expression

The Detox Support Stack: BPC-157 + KPV + LL-37 + Larazotide

A four-peptide combination addressing gut barrier integrity, systemic inflammation, and antimicrobia

The Fat Loss Stack: Tesamorelin + CJC-1295/Ipamorelin

Tesamorelin and CJC-1295/Ipamorelin both target the GH axis but through complementary timing and rec

The Fertility Stack: Kisspeptin-10 + Gonadorelin + Oxytocin

A three-peptide protocol targeting the hypothalamic-pituitary-gonadal (HPG) axis at multiple levels.

The GH Stack: CJC-1295 + Ipamorelin

The dual-pathway growth-hormone stack. CJC-1295 (GHRH analog) opens the pituitary somatotroph; Ipamo

The Gut Healing Stack: BPC-157 + KPV + Larazotide

The gut healing stack combines three peptides targeting distinct aspects of intestinal repair: BPC-1

The Hair Restoration Stack: GHK-Cu + Thymosin Beta-4

GHK-Cu and Thymosin Beta-4 (TB-500) target complementary mechanisms in hair follicle biology — coppe

The Healing Stack: BPC-157 + TB-500

The canonical regenerative-peptide pairing. BPC-157 and TB-500 operate through non-overlapping biolo

Immune Support Stack

A combination approach targeting immune function through three complementary mechanisms: adaptive im

The Joint Repair Stack: BPC-157 + Pentosan Polysulfate + TB-500

A comprehensive joint-repair protocol targeting all layers of joint pathology: BPC-157 for periartic

The Longevity Stack: Epitalon + MOTS-c + SS-31

Three peptides targeting different hallmarks of aging: Epitalon for telomerase activation and pineal

The Men's Hormone Stack: CJC-1295/Ipamorelin + Gonadorelin + Kisspeptin-10

A three-peptide protocol designed to optimize the male hormonal axis without exogenous testosterone.

The Metabolic Stack: GLP-1 + GHS

A newer 'metabolic recomposition' pairing some practitioners use: a GLP-1 agonist for appetite and t

The Mitochondrial Stack: SS-31 + MOTS-c + Humanin

Three mitochondria-targeted peptides addressing different aspects of mitochondrial dysfunction. SS-3

The Mood & Anxiety Stack: Selank + NA-Selank-Amidate + DSIP + Oxytocin

A four-peptide anxiolytic and mood-stabilizing protocol. Selank modulates GABA and serotonin signali

The Neuroprotection Stack: Cerebrolysin + Semax + Pinealon

The neuroprotection stack combines three neuropeptide approaches with complementary mechanisms — cer

The Nootropic Stack: Semax + Selank + GH-Axis Support

A three-tier nootropic peptide stack targeting cognitive performance through complementary mechanism

The Post-Surgery Recovery Stack: BPC-157 + TB-500 + Thymosin Alpha-1

The post-surgery recovery stack combines the established BPC-157 + TB-500 tissue-repair pairing with

The Sexual Health Stack: PT-141 + Kisspeptin-10

PT-141 and Kisspeptin-10 target complementary aspects of sexual function — central desire pathways a

The Skin Rejuvenation Stack: GHK-Cu + GH-Axis + Collagen

A multi-level skin rejuvenation protocol combining topical signaling (GHK-Cu), systemic GH-axis elev

The Sleep Stack: DSIP + Ipamorelin

DSIP (Delta Sleep-Inducing Peptide) and ipamorelin target complementary aspects of sleep optimizatio

The Stress Resilience Stack: Selank + DSIP + Semax

A three-peptide stack targeting different dimensions of the stress response: Selank for anxiolysis a

The Tendon Repair Stack: BPC-157 + TB-500 + GHK-Cu

A three-peptide protocol targeting tendon biology specifically. BPC-157 upregulates growth hormone r

The Thymic Regeneration Stack: Thymosin Alpha-1 + Thymalin + Thymulin

Three thymic peptides targeting the age-related involution of the thymus gland. Thymosin alpha-1 enh

The Weight Loss Stack: Semaglutide/Tirzepatide + Tesamorelin

This weight loss stack combines GLP-1 receptor agonist therapy (semaglutide or tirzepatide) with the

The Women's Hormonal Stack: Kisspeptin + BPC-157 + Thymosin Alpha-1

A three-peptide combination addressing women's hormonal health through hypothalamic signaling restor

The Wound Care Stack: BPC-157 + GHK-Cu + TB-500 + Collagen Peptides

A four-component protocol covering the full wound healing cascade. BPC-157 promotes angiogenesis and

Browse All peptide Products

Search

Search across products, blog posts, wiki articles, and more.